Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:11:04.357Z.
Consensus retrieved: 2026-10-06T09:34:17.782Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:11:04.357Z.
Quote observation: 2026-10-06T16:06:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d2f321814d39ccd237e1b3193eb134ce5d47974bdf154c870c7a61085da6207a
Forward PE Ratio (N/A) = Dated Quote Price ($2.07) / Consensus Forward EPS ($-1.36)
FORWARD PE RATIO
N/A
Biomerica, Inc.
Market Cap
$6.40M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Biomerica, Inc. (BMRA) | $6.40M | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.43M | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.49M | N/A |
| Femasys Inc. (FEMY)vs › | $6.24M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.66M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.74M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.80M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.93M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.91M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-05-31
At the dated quote price of $2.07, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-05-31 | $-1.36 | $-1.36 – $-1.36 | 1 | n/m |
| 2028-05-31 | $-1.28 | $-1.28 – $-1.28 | 1 | n/m |
| 2029-05-31 | $-2.00 | $-2.00 – $-2.00 | 1 | n/m |
| 2030-05-31 | $-2.05 | $-2.05 – $-2.05 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute